ref": "b0_0" } , { "ref": "b0_1", "citations": [ "18" ], "title": "FDA-labeled indications (excerpt)", "intro": "Covered per FDA or guideline-based indications described in these sections when documentation supports the indication:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"FDA-indicated disease states included in this excerpt\",\"text\":\"Includes relapsed/refractory classical Hodgkin lymphoma; recurrent locally advanced or metastatic Merkel cell carcinoma; unresectable or metastatic MSI-H/dMMR solid tumors after prior treatment with no satisfactory alternatives; TMB-H (≥10 mut/Mb) solid tumors after prior treatment with no satisfactory alternatives; multiple NSCLC indications including combination with chemotherapy or single-agent use for PD-L1 TPS thresholds; unresectable advanced/metastatic malignant pleural mesothelioma in combination with pemetrexed and platinum; PMBCL refractory or relapsed after ≥2 prior lines.\",\"threshold\":\"\",\"note\":\"Each indication requires the specific supporting biomarker, prior-line, or combination context as described in the label or NCCN guidance.\"}" ] }, { "ref": "b0_2", "citations": [ "28", "29", "30" ], "title": "NSCLC — labeled and guideline-aligned uses", "intro": "Covered with criteria for NSCLC:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"NSCLC coverage nodes\",\"text\":\"First-line combinations: pembrolizumab + pemetrexed + platinum for nonsquamous NSCLC without EGFR/ALK aberrations; pembrolizumab + carboplatin + paclitaxel or nab-paclitaxel for squamous NSCLC. First-line single-agent pembrolizumab for metastatic NSCLC with PD-L1 TPS ≥50% and no EGFR/ALK aberrations. Single-agent pembrolizumab for metastatic NSCLC with PD-L1 TPS ≥1% for disease progression after platinum chemotherapy (with prior targeted therapy for EGFR/ALK if present). Also indicated for certain neoadjuvant/adjuvant settings per label.\",\"threshold\":\"PD-L1 TPS thresholds as specified\",\"note\":\"Requires documented PD-L1 and genomic testing for EGFR/ALK/other actionable aberrations where relevant.\"}" ] }, { "ref": "b0_3", "citations": [ "35", "24" ], "title": "MSI-H/dMMR and TMB-H solid tumors", "intro": "Biomarker-driven solid tumor coverage (basket approvals and guideline extensions):", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"MSI-H/dMMR and TMB-H solid tumors\",\"text\":\"Pembrolizumab is indicated for unresectable or metastatic MSI-H/dMMR solid tumors that have progressed following prior treatment and have no satisfactory alternatives; also indicated for TMB-H tumors (≥10 mut/Mb) with progression following prior treatment and no satisfactory alternatives. NCCN provides additional 2A recommendations for certain tumor types (e.g., ovarian, small bowel, testicular, bone cancers) in MSI-H/dMMR or TMB-H contexts.\",\"threshold\":\"MSI-H/dMMR and TMB ≥10 mut/Mb\",\"note\":\"Pediatric CNS MSI-H safety not established per label.\"}" ] }, { "ref": "b0_4", "citations": [ "20", "21", "33" ], "title": "Selected tumor-specific coverage notes", "intro": "Melanoma and renal cell carcinoma coverage context:", "nodes": [ "{\"operator\":\"any\",\"n\":0,\"label\":\"Melanoma\",\"text\":\"Pembrolizumab is FDA indicated for unresectable or metastatic cutaneous melanoma and as adjuvant therapy for Stage IIB/IIC/III after complete resection; NCCN supports single-agent pembrolizumab across lines and in combination with ipilimumab as recommended for second-line or subsequent therapy in certain contexts.\",\"threshold\":\"ECOG PS 0-2 cited in guidance\",\"note\":\"BRAF mutation status relevant for sequencing with targeted therapy.\"}" , "{\"operator\":\"any\",\"n\":0,\"label\":\"Renal cell carcinoma\",\"text\":\"Pembrolizumab is FDA approved in combination with axitinib as first-line treatment of advanced RCC and as adjuvant therapy in intermediate-high or high risk post-nephrectomy; NCCN endorses combinations with lenvatinib or axitinib in various settings.\",\"threshold\":\"\",\"note\":\"\"}" ] }, { "ref": "b0_5", "citations": [ "54" ], "title": "Cervical cancer (FIGO 2014 Stage III-IVA) with CRT", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Cervical cancer concurrent chemoradiation criteria\",\"text\":\"Individual has FIGO 2014 Stage III-IVA cervical cancer AND using in combination with chemoradiotherapy (cisplatin or carboplatin plus EBRT followed by brachytherapy) AND no prior definitive surgery, radiation, or systemic therapy for cervical cancer AND has not received treatment with another anti-PD-1/PD-L1 agent AND is not receiving systemic immunosuppressant therapy for autoimmune disease or chronic condition\",\"children\":[]}" ] }, { "ref": "b0_6", "citations": [ "55" ], "title": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"CLL/SLL pembrolizumab use\",\"text\":\"Individual has CLL/SLL AND using as single agent OR in combination with ibrutinib AND using for histologic (Richter) transformation to diffuse large B-cell lymphoma AND has one of: del(17p)/TP53 mutation OR chemotherapy refractory OR unable to receive chemoimmunotherapy\",\"children\":[]}" ] }, { "ref": "b0_7", "citations": [ "55", "56", "57" ], "title": "Colorectal cancer (dMMR/MSI-H) coverage", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Colorectal dMMR/MSI-H pembrolizumab\",\"text\":\"Individual has colorectal cancer AND using as monotherapy AND one of: primary treatment for unresectable metachronous metastases after prior adjuvant FOLFOX/CapeOX within 12 months OR subsequent therapy for unresectable locally advanced or metastatic disease after oxaliplatin/irinotecan/fluoropyrimidine therapy OR first-line for unresectable advanced/metastatic disease (dMMR/MSI-H only) AND individual has not received another anti-PD-1/PD-L1 agent AND ECOG 0-2\",\"children\":[]}" ] }, { "ref": "b0_8", "citations": [ "58", "61" ], "title": "Advanced/metastatic colorectal and small bowel adenocarcinoma (biomarker-driven)", "intro": "Covered when ALL of the following are met", "nodes": [ "{\"operator\":\"all\",\"label\":\"Advanced colorectal with biomarkers\",\"text\":\"Individual has advanced/metastatic colorectal cancer AND using as single agent AND has dMMR or MSI-H or POLE/POLD1 mutation with ultra-hypermutated phenotype (e.g., TMB > 50 mut/Mb) AND has not received another anti-PD-1/PD-L1 agent AND ECOG 0-2 AND not on systemic immunosuppressant therapy\",\"children\":[]},{\"operator\":\"all\",\"label\":\"Small bowel adenocarcinoma biomarker-driven use\",\"text\":\"Individual has advanced/metastatic small bowel adenocarcinoma AND using as single agent for locally unresectable or medically inoperable dMMR/MSI-H or POLE/POLD1 ultra-hypermutated tumor AND has no previous checkpoint inhibitor exposure\",\"children\":[]}]